Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

9.1%

2 terminated/withdrawn out of 22 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

18%

4 trials in Phase 3/4

Results Transparency

39%

7 of 18 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 1

13(59.1%)

Phase 2

5(22.7%)

Phase 3

3(13.6%)

Phase 4

1(4.5%)

22Total

Phase 1(13)

Phase 2(5)

Phase 3(3)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT04360681Phase 2Completed

Lofexidine Combined With Buprenorphine for Reducing Symptoms of PTSD and OU Relapse in Veterans

Role: collaborator

NCT05993299Phase 2Active Not Recruiting

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Role: lead

NCT07321912Phase 2Not Yet Recruiting

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Role: collaborator

NCT06711640Phase 1Withdrawn

A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects

Role: lead

NCT04070157Phase 2Terminated

Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Role: lead

NCT04188730Phase 1Completed

A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

Role: lead

NCT02363998Phase 3Completed

Open-Label, Safety Study of Lofexidine

Role: lead

NCT01863186Phase 3Completed

Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal

Role: lead

NCT04126083Phase 4Completed

Lofexidine for Adults Undergoing Lumbar Spine Surgery

Role: collaborator

NCT04056182Phase 2Completed

Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment